AFAndreas G. Franke

Andreas G. Franke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas G. Franke has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • (Psycho-)Stimulanzien in Psychopharmakotherapie und pharmakologischem Neuroenhancement und ihre suchtmedizinischen Implikationen

    by Michael Soyka, Andreas G. Franke

    Zusammenfassung. Zielsetzung: Ziel des Artikels ist es, dem Leser eine Übersicht über die Wirkungen und die Verbreitung von (Psycho-)Stimulanzien zur Verbesserung kognitiver Funktionen bei Gesunden (pharmakologisches kognitives Neuroenhancement [PCE]) unter besonderer Berücksichtigung suchtmedizinischer Aspekte zu geben. Methodik: Systematische Literaturrecherche via PubMed nach Psychostimulanzien („stimulants“), die zur geistigen Leistungssteigerung („cognitive enhancement“) eingesetzt werden, und Literaturrecherche in aktuellen Büchern aus dem Bereich Sucht. Ergebnisse: Nach heutigem Kenntnisstand spielt die Gruppe der (Psycho-)Stimulanzien die zentrale Rolle beim Phänomen des PCE. Hierzu zählen sowohl die frei verkäuflichen Methylxanthine wie Koffein aber auch illegale bzw. verschreibungspflichtige Amphetamine und deren Derivate wie Methylphenidat, die zum PCE missbraucht werden. Gleichermaßen werden die verschreibungspflichtigen Substanzen dieser Gruppe aber auch gemäß ihrer Indikation psychopharmakotherapeutisch angewendet. Dabei liegt das Ziel der Psychopharmakotherapie in der Verbesserung der vorliegenden Symptome und im Bezug zu krankheitsbedingten kognitiven Einbußen in der Wiederherstellung des krankheitsbedingt verloren gegangenen kognitiven Funktionsniveaus mit einem für die jeweilige psychische Erkrankung indizierten Medikament. Ziel des PCE ist hingegen die Verbesserung der kognitiven Leistungsfähigkeit verschiedener kognitiver Domänen wie z. B. Vigilanz, Konzentration und Gedächtnis über ein „normales Maß“ hinaus. Schlussfolgerung: Der Artikel zeigt die Überschneidung der (Psycho-)Stimulanzien zur Pharmakotherapie und zum PCE und verdeutlicht insbesondere das Suchtrisiko bei Kranken und Gesunden.


  • Familiäre Ressourcen und Strategien bei Krebs

    by Stefanie Neumann, Andreas G. Franke

    Hintergrund Familien, in denen eines ihrer Mitglieder an einer malignen Neoplasie erkrankt, sind mit psychosozialen Folgeproblemen konfrontiert. Ihre Versorgung ist insbesondere im ländlichen Raum noch insuffizient. Fragestellung Die Studie untersucht, welche Strategien und psychosoziale Ressourcen das System Familie aktiviert und anwendet, um ihre Balance zu halten. Material und Methode In narrativ-orientierten Interviews berichteten 36 Neoplasie-Patienten und ihre Familienangehörigen über die gemeinsame Krankheitserfahrung; Art und Stadium der Neoplasie bildeten keine relevanten Kriterien. Die Auswertung erfolgte deskriptiv mittels qualitativer Inhaltsanalyse nach Mayring und mithilfe der Software MAXQDA 11. Ergebnisse Die untersuchten Familien aktivierten zahlreiche psychosoziale Ressourcen; insbesondere in Form „emotionalen Beistands“, „praktischer Alltagshilfe“ und „krankheitsbezogener Beratung“. Zur Bewältigung der Krankheitserfahrung nutzen die meisten Familien die Strategien „Sinngebung“ und „Haltung bewahren“ (kognitiv), „Optimismus“ (emotional) sowie „krankheitsbezogenes ,Zupacken‘“ (handlungsbezogen). Schlussfolgerung Die Familien stellten umfangreiche psychosoziale Ressourcen bereit, die sich aus der Komplexität der kausalen Belastungen durch die Neoplasie erklären lassen. Sie bewältigen die Neoplasie unter dem Einschluss von Emotion, Kognition und Handlungen. Die Familien suchten insbesondere nach kognitiv individuellen Erklärungen der Erkrankung und konstruierten subjektive Krankheitskonzepte, um eine emotionsregulative Wirkung zu erzielen. Familien mit von Neoplasien betroffenen Familienmitgliedern aktivieren psychosoziale Ressourcen und bewältigen die Anforderungen primär emotional sowie durch kognitive Umstrukturierungen und subjektive Erklärungen. Background Families in that a member has been diagnosed with a malignant neoplasia are confronted with psychosocial problems. Especially in rural areas, their supply is still insufficient. Objectives The study examines, which coping strategies and psychosocial resources the family system has to activate to maintain or regain their family balance. Methods 36 patients suffered from a malignant neoplasia (partly with family members) were surveyed using a narrative-oriented interview procedure about their family illness experience. Type and stage of the respective neoplasia have not been relevant criteria. Interviews were analyzed qualitatively and descriptively according to Mayring using software MAXQDA 11. Results The surveyed families activated numerous psychosocial resources; particularly of 3 types: “emotional assistance”, “practical everyday life assistance” and “disease related consulting”. To cope with the disease experience, most families use the strategies “giving meaning” and “attitude preserve” (cognitive), “optimism” (emotional) and “disease-related ‘grab’” (activity related). Conclusion Families provide comprehensive psychosocial resources which are determined by the complexity of the causal stress of the neoplasia. They “manage” the neoplasia is influenced by the inclusion of emotion, cognition and activity. Families searched for cognitively individual explanations of the disease and constructed subjective concepts of the respective disease to achieve an emotionally regulated effect. Families with family members suffered from a malignant neoplasia activate comprehensive psychosocial resources and cope with the demands primarily by emotional and cognitive restructuring and subjective explanation models.


  • Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial

    by Andreas G. Franke, Patrik Gränsmark, Alexandra Agricola, Kai Schühle, Thilo Rommel, Alexandra Sebastian, Harald E. Balló, Stanislav Gorbulev, Christer Gerdes, Björn Frank, et al.


  • Open Access

    Pharmacological Neuroenhancement: teachers’ knowledge and attitudes–Results from a survey study among teachers in Germany

    by Andreas G. Franke, Sophie Lehmberg, Michael Soyka

    Pharmacological neuroenhancement (PN) is a topic of increasing importance. Its prevalence rates range from 1 % to more than 20 %. Students are a group that shows exceptionally high prevalence rates. However, little is known about teachers’ knowledge, management, attitudes and ethical judgements regarding PN. A web-based survey containing 40 closed questions was developed. All teachers working at all private and public schools in Mecklenburg-Vorpommern, a state in northeastern Germany, were invited to participate after their respective school offices were contacted by telephone, email and mail. In total, 255 teachers participated in the survey. Of those, 73.3 % had already heard about PN in general, and 68.2 % had heard about PN in students. Their sources of knowledge were digital media such as TV (73.8 %) and the internet (40.6 %) and print media (64.7 %); their own students informed 29.9 % of the teachers about PN in general and 35.6 % of them about PN among students. Furthermore, 34.9 % of the surveyed teachers were convinced that PN substance use was ineffective in general, and 51.8 % of the surveyed teachers believed that PN substances were ineffective in achieving better grades. Only 1.2 % thought that none of the so-called PN substances could lead to addiction, and 37.6 % would classify PN substance use as general drug misuse. The highest values regarding risk of addiction were observed for illicit drugs. The prevalence of PN substance use was evaluated to be very low and to be significantly higher in male, highly skilled and college/university students. In total, 1.6 school lessons per year were used to discuss PN. Finally, 55.7 % of the surveyed teachers believed that performance-enhancing substances should be forbidden at schools. Teachers, as an integral part of the education of children and adolescents, often know about PN substances and mostly refuse their use being afraid about the risk of addiction. However, regarding effects as well as side effects of PN substances, teachers have very different opinions. Furthermore, they seem to underestimate the prevalence among their students and broach the topic infrequently. Teachers should be sensitized for high prevalence rates and should broach the topic of PN more frequently to their students to prevent potential misuse of PN substances.


  • Cannabis for Cognitive Enhancement as a New Coping Strategy? Results From a Survey of Students at Four Universities in Germany

    by Andreas G. Franke, Patrik Roser, Klaus Lieb, Jochen Vollmann, Jan Schildmann

    Background: Cognitive Enhancement (CE) is often discussed in relation to stimulant drugs, such as amphetamines (AMPH). However, there is some evidence that cannabis (CAN) can be used for CE. Objective: This study compares the knowledge, prevalence, and perceived effects of and factors associated with the knowledge of or use of CAN versus AMPH for CE among undergraduate students at four German universities. Methods: A survey was taken of 1,538 students at four German universities. It investigated their knowledge and use of CAN and AMPH for CE as well as associated factors. Descriptive and analytic (Mann–Whitney-U test, Fisher's exact test, logistic regression) statistics were obtained using SPSS. Results: Responses were obtained from 1,026 participants (57.2%) at three universities from the Universitätsallianz Metropole Ruhr (UAR) (Bochum, Dortmund, Duisburg-Essen) and 512 respondents (68.3%) in Mainz. We observed lifetime prevalence rates of 3.5% for the use of CAN and 2.1% for the use of AMPH for the purpose of CE. CAN users perceived pressure to perform as more of a burden than AMPH users (mean: 3.2, CAN users: 4.7, AMPH: 2.9; p =.042). CAN users used the substances for studying for exams significantly less often than AMPH users (p =.025), and CAN users perceived less of an enhancing effect of the drug compared to AMPH users (p <.001). Conclusions: A considerable number of students report having used CAN for CE. However, our research indicates differences in perceptions and experiences of CE between CAN and AMPH users. Further research on the role of CAN for CE and conceptual analyses to differentiate between different understandings of CE are warranted.


  • Open Access

    Pharmacological Neuroenhancement in the Field of Economics—Poll Results from an Online Survey

    by Pavel Dietz, Michael Soyka, Andreas G. Franke

    Introduction: The use of over-the-counter, prescription, and illicit drugs to increase attention, concentration or memory – often called (pharmacological) neuroenhancement – shows a broad range of prevalence rates among students. However, very little data is available on neuroenhancement among employed persons. The aim of this study was to provide first data on substance use for neuroenhancement among readers of the German “Handelsblatt” coming from the field of economics. Methods: Readers of the online edition of the Handelsblatt, a leading print and online medium for the field of economics, were invited to participate in a survey via a link on the journal homepage to complete a web-based questionnaire. Within the questionnaire, participants were asked for their gender, current age, current professional status, hours of work per week, prevalence rates of substance use for the purpose of neuroenhancement as well as for reasons of its use. Binary regression analyses with stepwise forward selection were used to predict the dependent variables “use of illicit and prescription drugs for neuroenhancement” (yes/no), “use of over-the-counter drugs for neuroenhancement” (yes/no), and “use of any drug for neuroenhancement” (yes/no). Results: A total of 1,021 participants completed the anonymous survey. Lifetime prevalence for the use of any drug for neuroenhancement was 88.0% and for the use of illicit and prescription drugs for neuroenhancement 19.0%. Reasons and situations that predicted neuroenhancement with illicit and prescription drugs were “curiosity”, “to enhance mood”, ”for a confident appearance”, “stress/pressure to perform”, and “deadline pressure”. Discussion: The study shows that neuroenhancement with drugs is a widespread and frequent phenomenon among people belonging to the professional field of economics. Given in the literature that the use of drugs, especially prescription and illicit drugs, may be associated with side effects, the high epidemic of drug use for neuroenhancement also shown in the present paper underlines the new public health concern of neuroenhancement.


  • Die krebserfahrene Familie in der Sozialen Arbeit

    by Stefanie Neumann, Andreas G. Franke

  • The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective

    by A. G. Franke, R. Northoff, E. Hildt

    Pharmacological neuroenhancement (PN) describes the use of psychoactive drugs for the purpose of enhancing cognition (e. g., fatigue, concentration, memory etc.) by healthy subjects without medical need. Drugs used for this purpose can be divided into freely available, over-the-counter drugs (e. g., methylxanthines such as caffeine), prescription drugs (e. g., antidementia drugs, methylphenidate) and illicit drugs (e. g., illicit amphetamines). Clinical studies have shown that the aforementioned substances only have limited pro-cognitive effects and have considerable safety risks and side effects. The German judicial perspective shows legal differences between substances (drugs, food, food supplements, fortified food) that can be bought in a supermarket, drugs that can be bought in a pharmacy as over-the-counter- (OTC-) drugs, drugs with or without the need for a prescription and illicit drugs. Supermarket drugs and fortified food can be sold freely and follow the general rules of civil and penal law; regarding acquisition, parents are responsible for their children. OTC drugs require special information about therapy. Regarding prescription drugs, there are legal problems caused by an off-label use and the non-medical purposes of PN drugs. Furthermore, prescription stimulants for PN are governed by the specialized law for narcotics, and their use might be punished. Beyond the general lack of rules for regulation for PN drug use there are specific needs for prevention (e. g., control of the black market, etc.). Possible future policy will depend, among others, on the probability with which effective PN drugs with an acceptable risk-benefit ratio will be available, on individual and societal implications, and on public opinion towards PN. While 4 different general policy scenarios can be identified, it is important to advance a broad societal debate on PN to collect relevant empirical data and to address enhancement-related conceptual issues.


  • The Use of Caffeinated Substances by Surgeons for Cognitive Enhancement

    by Andreas G. MD Franke, Christiana Dipl-Soz Bagusat, Carolyn McFarlane, Teresina Tassone-Steiger, Werner Kneist, Klaus Lieb

    Objective: To investigate the use of coffee, caffeinated drinks, and caffeine tablets for pharmacological cognitive enhancement (CE) among surgeons. Background: Surgeons have demanding workloads, and the resulting fatigue and concentration deficits can lead to medical errors. Some surgeons use substances that promote wakefulness to counteract these effects. Methods: A total of 3306 surgeons who attended 5 international conferences in 2011 were surveyed regarding their use of coffee, caffeinated drinks, and caffeine tablets for CE and potential factors derived from professional and private life using an anonymous self-report questionnaire. In this study, we were only interested in surgeons working in hospitals; therefore, 951 questionnaires were statistically analyzed. Results: The most prevalent reason for using caffeine of any kind was to reduce fatigue (54.3%). Further prevalent reasons are working the night shift (32.2%) and overly long and excessive work hours (31.7%). Lifetime, past-year, past-month, and past-week prevalence was 66.8%, 61.9%, 56.9%, and 50.5%, for coffee use; 24.2%, 15.4%, 9.9%, and 6.1%, for caffeinated drinks; and 12.6%, 5.9%, 4.7%, and 3.8%, respectively, for caffeine tablets. Caffeine use was associated with lower age, male sex, divorced marital status, living with children, lack of satisfaction with professional status, pressure to perform in private life, and pressure perceived to be harmful to one's own health. Conclusions: Surgeons often use caffeinated substances to cope with fatigue and long working hours. Coffee use was more prevalent than the use of caffeinated drinks and caffeine tablets.


  • Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin

    by A. G. Franke, M. Soyka

    Pharmakologisches „Cognitive Enhancement“ (CE) oder auch „pharmakologisches Neuroenhancement“ (PN) beschreibt die Einnahme diverser Substanzen durch Gesunde mit dem Ziel, die eigene geistige Leistungsfähigkeit vor allem bezüglich Vigilanz, Aufmerksamkeit, Konzentration, Gedächtnis und Motivation zu verbessern. Die eingenommenen Substanzen lassen sich in Stimulanzien (Methylxanthintyp wie Koffein, Amphetamintyp wie Methylphenidat, Amphetamine und Modafinil) und Nicht-Stimulanzien (verschreibungspflichtige Medikamente wie Antidementiva, Antidepressiva und frei verkäufliche Präparate wie Phytopharmaka, z. B. Ginkgo biloba) unterteilen. Die Einnahmeprävalenzen weisen je nach Studie und Substanz große Unterschiede auf und liegen zwischen 1 % Lebenszeitprävalenz und 20 % Ein-Jahres-Prävalenz. Das Missbrauchs- und Abhängigkeitsrisiko ist sehr unterschiedlich und scheint bei Nicht-Stimulanzien zu vernachlässigen zu sein, während es bei Stimulanzien vom Methylxanthintyp, v. a. aber vom Amphetamintyp nicht zu unterschätzen ist. Diese Übersichtsarbeit stellt die o. g. Substanzen mit ihren größtenteils auf einfache kognitive Teilleistungen begrenzten klinischen Effekten sowie suchtmedizinische Aspekte der zum PN eingesetzten Substanzen dar. Pharmacological “cognitive enhancement” (CE) and “pharmacological neuroenhancement” (PN) are different terms to describe the use of diverse substances by healthy individuals aiming at an increase of individual cognitive skills. Targets of CE are an increase of vigilance, attention, concentration, memory and motivation. Substances used for pharmacological CE can be divided into two categories: stimulants and non-stimulants. The sub-group of methylxanthines like caffeine as well as the sub-group of amphetamines like prescription and illicit amphetamine as well as methylphenidate and modafinil belongs to the group of stimulants; antidementives, antidepressants, phytopharmaceutical products like Ginkgo biloba etc. belong to the group of non-stimulants. Prevalence rates depend on the (type of) study and (group of) substances used for CE. And they range from a 1 % lifetime prevalence rate up to 20 % one-year prevalence rate. This review presents stimulant and non-stimulant substances, their limited clinical effects on cognitive skills as well as their prevalence rates and the aspect of misuse and addiction of the above-mentioned substances which belongs to their respective category.